GSK plc (NYSE:GSK) is one of the best affordable healthcare stocks to buy now. GSK plc (NYSE:GSK) announced on December 19 an ...

GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On December 10, HSBC analyst ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

GSK PLC closed 11.41% short of its 52-week high of £20.58, which the company reached on December 19th.

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.

SEOUL, Dec 22 (Reuters) - South Korea's Samsung Biologics (207940.KS) said on Monday it is acquiring its first U.S. drug ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant, which it rejected last September, triggering a very public dispute with ...

GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...

Samsung Biologics has agreed to buy GSK's Human Genome Sciences for $280 million, expanding the company's footprint into the U.S. market.